Message to the Friedreich ataxia Community

Dear Advocacy Partners,

We are pleased to share a press release announcing updates to our cardiac gene therapy portfolio and Q3 2024 financial results. You can read the full details here.

Highlights include:

- Reached agreement with the Food and Drug Administration (FDA) on using left-ventricular mass index (LVMI) and frataxin protein expression levels as endpoints to support regulatory approval of LX2006

- LX2006 has also received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for the treatment of Friedreich ataxia (FA) cardiomyopathy, which could lead to faster development and more frequent touchpoints with the FDA

- Finished enrolling participants in the LX2006 SUNRISE-FA Phase 1/2 trial, with four people treated in cohort 3 (the highest dose cohort). A total of 16 participants have received LX2006 in two studies (SUNRISE-FA and Weill Cornell study)

We greatly appreciate our study investigators and the courageous trial participants and caregivers who have helped us get to this point. Lexeo is committed to furthering our goal of targeting the underlying cause of genetic diseases and creating a world where genetics isn't destiny.

We will keep this community updated as we continue our work with regulatory authorities to design and implement clinical studies, as well as enroll participants in ongoing and future trials. For more information or any questions, please contact clinicaltrials@lexeotx.com.

Thank you for your partnership and working with Lexeo to help solve the unmet need in Friedreich ataxia cardiomyopathy.

We wish you a wonderful holiday season and best wishes for 2025.

The Lexeo Team